Exanthem disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: EXN002 MIFTS: 62	Exanthem Categories: Infectious diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs Download Expand all tables

Sources

Aliases & Classifications for Exanthem

MalaCards integrated aliases for Exanthem:

Name: Exanthem ¹² ¹⁴

Exanthema ¹² ⁴¹

Rashes ⁴⁰

Rash ¹²

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Skin diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified

Symptoms and signs involving the skin and subcutaneous tissue

Rash and other nonspecific skin eruption

External Ids:

Disease Ontology ¹² DOID:0050486

ICD10 ³² R21

ICD9CM ³⁴ 782.1

MeSH ⁴¹ D005076

NCIt ⁴⁶ C111884 C39594

SNOMED-CT ⁶⁴ 112625008 139684003 158230006 more

UMLS ⁶⁹ C0015230

Sources

Summaries for Exanthem

MedlinePlus : ⁴⁰ A rash is an area of irritated or swollen skin. Many rashes are itchy, red, painful, and irritated. Some rashes can also lead to blisters or patches of raw skin. Rashes are a symptom of many different medical problems. Other causes include irritating substances and allergies. Certain genes can make people more likely to get rashes. Contact dermatitis is a common type of rash. It causes redness, itching, and sometimes small bumps. You get the rash where you have touched an irritant, such as a chemical, or something you are allergic to, like poison ivy. Some rashes develop right away. Others form over several days. Although most rashes clear up fairly quickly, others are long-lasting and need long-term treatment. Because rashes can be caused by many different things, it's important to figure out what kind you have before you treat it. If it is a bad rash, if it does not go away, or if you have other symptoms, you should see your health care provider. Treatments may include moisturizers, lotions, baths, cortisone creams that relieve swelling, and antihistamines, which relieve itching.

MalaCards based summary : Exanthem, also known as exanthema, is related to aseptic meningitis and cryopyrin-associated periodic syndrome. An important gene associated with Exanthem is CD40LG (CD40 Ligand), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Cetuximab and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and lung, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : ⁷² An exanthem or exanthema (from Greek ἐξάνθημα exánthēma, \"a breaking out\") is a widespread rash... more...

Sources

Related Diseases for Exanthem

Diseases in the Exanthem family:

Bacterial Exanthem

Viral Exanthem

Diseases related to Exanthem via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 279)

#	Related Disease	Score	Top Affiliating Genes
1	aseptic meningitis	30.5	IL1RN NLRP3 TNF
2	cryopyrin-associated periodic syndrome	30.2	CRP IL1RN NLRP3
3	meningoencephalitis	30.2	CD40LG CD79A TLR9
4	meningitis	30.2	CD40LG CRP NLRP3 TLR9 TNF
5	pneumonia	30.1	CD40LG CRP TLR9 TNF
6	myeloma, multiple	30.0	CD40LG CD79A HRAS TLR9
7	acquired immunodeficiency syndrome	29.6	CD40LG CD79A IL2 TNF
8	mumps	29.5	CD40LG IL2 TNFRSF1A
9	brucellosis	29.3	CD40LG CRP IL1RN IL2 TNF
10	exanthema subitum	12.3
11	viral exanthem	12.1
12	bacterial exanthem	11.9
13	hand, foot and mouth disease	11.3
14	contagious pustular dermatitis	11.0
15	severe cutaneous adverse reaction	11.0
16	selective igg deficiency disease	10.7	CD40LG CD79A
17	c1q nephropathy	10.7	CD40LG CD79A
18	meningovascular neurosyphilis	10.6	CD40LG CD79A
19	alpha chain disease	10.6	CD40LG CD79A
20	brill-zinsser disease	10.6	CD40LG CD79A
21	exudative glomerulonephritis	10.6	CD40LG CD79A
22	cork-handlers' disease	10.6	CD40LG CD79A
23	salpingo-oophoritis	10.6	CD40LG CD79A
24	breast intraductal proliferative lesion	10.6	EGFR ERBB2
25	early yaws	10.6	CD40LG CD79A
26	ventilation pneumonitis	10.6	CD40LG CD79A
27	chronic interstitial cystitis	10.6	CD40LG CD79A
28	axillary adenitis	10.6	CD40LG CD79A
29	cryofibrinogenemia	10.6	CD40LG CD79A
30	sigmoid neoplasm	10.6	HRAS KRAS
31	schnitzler syndrome	10.6	CD40LG IL1RN NLRP3
32	transient neonatal thrombocytopenia	10.5	CD79A TRIM21
33	ocular toxoplasmosis	10.5	CD40LG CD79A TLR9
34	conjunctival disease	10.5	CD40LG CD79A NLRP3
35	trichostrongyloidiasis	10.5	CD40LG CD79A
36	autoimmune disease of urogenital tract	10.5	CD40LG CD79A TLR9
37	subacute bacterial endocarditis	10.5	CD40LG CD79A
38	acute maxillary sinusitis	10.5	CD40LG CD79A CRP
39	hypersensitivity vasculitis	10.5	CD40LG CD79A CRP
40	intussusception	10.5	CD40LG CD79A CRP
41	heterophyiasis	10.5	CD40LG CD79A
42	hypersensitivity reaction type iii disease	10.5	CD40LG CD79A CRP
43	pyelitis	10.5	CD40LG CD79A CRP
44	lung adenoid cystic carcinoma	10.5	EGFR HRAS KRAS
45	mature b-cell neoplasm	10.5	CD40LG CD79A TLR9
46	immunoglobulin g deficiency	10.5	CD40LG CD79A
47	b cell deficiency	10.5	CD40LG CD79A TLR9
48	endocardium disease	10.5	CD40LG CD79A CRP
49	tumor suppressor gene on chromosome 11	10.5	EGFR ERBB2 KRAS
50	anterior scleritis	10.5	CD79A IL1RN TNFRSF1B

Graphical network of the top 20 diseases related to Exanthem:

Sources

Symptoms & Phenotypes for Exanthem

GenomeRNAi Phenotypes related to Exanthem according to GeneCards Suite gene sharing:

²⁵ (show all 18)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-2	10.4	HRAS EGFR KALRN KRAS MTOR
2	Decreased viability	GR00106-A-0	10.4	KRAS
3	Decreased viability	GR00221-A-1	10.4	HRAS KALRN KRAS MTOR MAP2K7 EGFR
4	Decreased viability	GR00221-A-2	10.4	HRAS KALRN KRAS
5	Decreased viability	GR00221-A-3	10.4	HRAS
6	Decreased viability	GR00221-A-4	10.4	KALRN MTOR EGFR
7	Decreased viability	GR00301-A	10.4	KALRN KRAS
8	Decreased viability	GR00342-S-1	10.4	KALRN MTOR MAP2K7
9	Decreased viability	GR00342-S-2	10.4	KALRN MTOR
10	Decreased viability	GR00342-S-3	10.4	KALRN
11	Decreased viability	GR00381-A-1	10.4	KALRN KRAS
12	Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance	GR00210-A	9.73	EGFR ERBB2 HRAS HSPG2 KALRN MTOR
13	Decreased cell migration	GR00055-A-1	9.72	EGFR HRAS KALRN KRAS MTOR
14	Decreased substrate adherent cell growth	GR00193-A-2	9.55	EGFR KALRN MAP2K7 MTOR
15	Decreased substrate adherent cell growth	GR00193-A-3	9.55	MAP2K7
16	Decreased viability with paclitaxel	GR00179-A-1	9.36	ERBB2 MTOR EGFR
17	Decreased viability with paclitaxel	GR00179-A-2	9.36	MTOR
18	Decreased viability with paclitaxel	GR00179-A-3	9.36	EGFR MTOR

MGI Mouse Phenotypes related to Exanthem:

⁴³ (show all 24)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.54	HSPG2 IL1RN IL2 KALRN KRAS MAP2K7
2	cellular	MP:0005384	10.48	CD40LG CD79A EGFR ERBB2 HSPG2 IL1RN
3	cardiovascular system	MP:0005385	10.46	EGFR ERBB2 HRAS HSPG2 IL1RN IL2
4	hematopoietic system	MP:0005397	10.44	CD40LG CD79A EGFR HSPG2 IL1RN IL2
5	immune system	MP:0005387	10.42	CD79A CRP EGFR HSPG2 IL1RN IL2
6	mortality/aging	MP:0010768	10.42	EGFR ERBB2 HRAS HSPG2 IL1RN IL2
7	growth/size/body region	MP:0005378	10.39	MTOR NLRP3 TNF TNFRSF1A TNFRSF1B EGFR
8	integument	MP:0010771	10.38	CD40LG EGFR ERBB2 HRAS HSPG2 IL1RN
9	behavior/neurological	MP:0005386	10.36	TNF TNFRSF1A TNFRSF1B ERBB2 HRAS HSPG2
10	endocrine/exocrine gland	MP:0005379	10.36	KRAS MAP2K7 MTOR TNF TNFRSF1A TNFRSF1B
11	digestive/alimentary	MP:0005381	10.33	EGFR ERBB2 HRAS HSPG2 IL2 KRAS
12	nervous system	MP:0003631	10.28	ERBB2 HRAS HSPG2 KALRN KRAS MAP2K7
13	craniofacial	MP:0005382	10.2	EGFR ERBB2 HRAS HSPG2 KRAS TNF
14	liver/biliary system	MP:0005370	10.16	CD79A EGFR HSPG2 IL2 KRAS NLRP3
15	neoplasm	MP:0002006	10.16	TNF TNFRSF1A TNFRSF1B CD79A EGFR ERBB2
16	muscle	MP:0005369	10.13	EGFR ERBB2 HSPG2 KALRN KRAS MTOR
17	limbs/digits/tail	MP:0005371	10.07	EGFR ERBB2 HSPG2 KRAS NLRP3 TNF
18	no phenotypic analysis	MP:0003012	10.06	MTOR TNF TNFRSF1A CD79A EGFR HRAS
19	renal/urinary system	MP:0005367	10.06	CD40LG CD79A EGFR HRAS KRAS MTOR
20	normal	MP:0002873	10.02	CD79A EGFR ERBB2 HRAS KALRN KRAS
21	reproductive system	MP:0005389	10	CD40LG EGFR ERBB2 IL1RN IL2 KALRN
22	respiratory system	MP:0005388	9.85	TNFRSF1A TNFRSF1B EGFR ERBB2 HRAS HSPG2
23	skeleton	MP:0005390	9.73	CD40LG EGFR ERBB2 HRAS HSPG2 IL1RN
24	vision/eye	MP:0005391	9.23	EGFR HSPG2 IL2 KRAS MAP2K7 TNF

Sources

Drugs & Therapeutics for Exanthem

Drugs for Exanthem (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 940)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Cetuximab

Approved

Phase 4,Phase 3,Phase 2,Phase 1

205923-56-4

56842117 2333

Fluorouracil

Approved

Phase 4,Phase 3,Phase 2,Phase 1

51-21-8

3385

Irinotecan

Approved, Investigational

Phase 4,Phase 2,Phase 1

97682-44-5, 100286-90-6

60838

Menthol

Approved

Phase 4,Phase 3

2216-51-5

16666

Zinc

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2

7440-66-6

32051 23994

Zinc oxide

Approved

Phase 4,Phase 3

1314-13-2

Apraclonidine

Approved

Phase 4,Phase 3

66711-21-5

2216

Vancomycin

Approved

Phase 4,Phase 3

1404-90-6

14969 441141

Gabapentin

Approved, Investigational

Phase 4,Phase 2

60142-96-3

3446

gamma-Aminobutyric acid

Approved, Investigational

Phase 4,Phase 2

56-12-2

119

Ketorolac

Approved

Phase 4

74103-06-3, 66635-83-4

3826

Latanoprost

Approved, Investigational

Phase 4

130209-82-4

5311221 5282380

Benzoyl peroxide

Approved

Phase 4,Phase 3,Phase 1,Phase 2

94-36-0

7187

Clindamycin

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1

18323-44-9

29029

Nevirapine

Approved

Phase 4,Phase 3,Phase 2

129618-40-2

4463

Prednisone

Approved, Vet_approved

Phase 4,Phase 2,Phase 3,Phase 1

53-03-2

5865

sodium fluoride

Approved

Phase 4,Phase 2

7681-49-4

Tacrolimus

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

104987-11-3

445643 439492

Salicylic acid

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

69-72-7

338

Sorafenib

Approved, Investigational

Phase 4,Phase 2

284461-73-0

216239 406563

Clobetasol

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

25122-41-2, 25122-46-7

5311051 32798

Triamcinolone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Early Phase 1

124-94-7

31307

Rifampin

Approved

Phase 4,Phase 1,Phase 2

13292-46-1

5381226 5458213

Sunitinib

Approved, Investigational

Phase 4,Phase 1

341031-54-7, 557795-19-4

5329102

Azithromycin

Approved

Phase 4,Phase 3,Phase 2,Early Phase 1

83905-01-5

53477736 447043 55185

Efavirenz

Approved, Investigational

Phase 4,Phase 3,Phase 1

154598-52-4

64139

Lidocaine

Approved, Vet_approved

Phase 4,Phase 3,Phase 1

137-58-6

3676

Petrolatum

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2

8009-03-8

Doxycycline

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

564-25-0

54671203

Acetaminophen

Approved

Phase 4,Phase 3,Phase 1,Phase 2

103-90-2

1983

Tazarotene

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

118292-40-3

5381

Azelaic acid

Approved

Phase 4,Phase 3,Phase 2,Phase 1

123-99-9

2266

Benzocaine

Approved, Investigational

Phase 4,Phase 2,Phase 3,Early Phase 1

1994-09-7, 94-09-7

2337

Hyaluronic acid

Approved, Vet_approved

Phase 4

9004-61-9

53477741 24759

Minocycline

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

10118-90-8

5281021

Betamethasone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2

378-44-9

9782

Pimecrolimus

Approved, Investigational

Phase 4,Phase 3,Phase 2

137071-32-0

17753757 6447131

Ephedrine

Approved

Phase 4,Phase 2

299-42-3

9294

Pseudoephedrine

Approved

Phase 4,Phase 2

90-82-4

7028

Apremilast

Approved, Investigational

Phase 4,Phase 3,Phase 2

608141-41-9

11561674

Peginterferon alfa-2a

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2

198153-51-4

5360545

Ribavirin

Approved

Phase 4,Phase 3,Phase 1

36791-04-5

37542

Artemether

Approved

Phase 4,Phase 2,Phase 3,Phase 1

71963-77-4

68911 119380

Lumefantrine

Approved

Phase 4,Phase 2,Phase 3,Phase 1

82186-77-4

6437380

Miconazole

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

22916-47-8

4189

Lamivudine

Approved, Investigational

Phase 4,Phase 3,Phase 2

134678-17-4

60825

Stavudine

Approved, Investigational

Phase 4

3056-17-5

18283

Everolimus

Approved

Phase 4,Phase 3,Phase 2,Phase 1

159351-69-6

6442177

Mycophenolate mofetil

Approved, Investigational

Phase 4,Phase 3,Phase 2

128794-94-5

5281078

Mycophenolic acid

Approved

Phase 4,Phase 3,Phase 2

24280-93-1

446541

Interventional clinical trials:

(show top 50) (show all 1872)

#	Name	Status	NCT ID	Phase	Drugs
1	Elmex Gel Efficacy in Preventing White Spot Lesions	Unknown status	NCT00268138	Phase 4	elmex gel
2	FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema	Unknown status	NCT01315990	Phase 4	FOLFIRI + Cetuximab
3	Trial Comparing Calmoseptine Ointment and Desitin Diaper Rash Paste in Diaper Dermatitis in Neonates and Infants	Unknown status	NCT02716415	Phase 4	Calmoseptine Ointment;Destin Maximum Strength 40% Zinc
4	Line Versus Spot Ablation in Persistent Atrial Fibrillation	Unknown status	NCT00196157	Phase 4
5	Micropulse Laser Trabeculoplasty Versus Selective Laser Trabeculoplasty for Treatment of Open Angle Glaucoma	Unknown status	NCT01956942	Phase 4
6	Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients	Unknown status	NCT02605213	Phase 4	Vancomycin;Placebo
7	A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder	Unknown status	NCT00837343	Phase 4	quetiapine fumarate tablet (Seroquel)
8	Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission	Unknown status	NCT01901666	Phase 4	Growth Hormone
9	Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome	Unknown status	NCT02424695	Phase 4	Gabapentin Enacarbil (GEn);Placebo
10	The Laser in Pseudoexfoliation (LIP) Study	Unknown status	NCT01704989	Phase 4	Prostagladin
11	Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris	Unknown status	NCT01448733	Phase 4	Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening
12	A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne	Unknown status	NCT01422785	Phase 4	clindamycin phosphate 1.2%/tretinoin 0.025% gel alone;clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
13	Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples)	Unknown status	NCT01260571	Phase 4	Benzoyl peroxide and sulfur
14	Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE)	Unknown status	NCT01553032	Phase 4	Erbitux®
15	Clinical Study to Evaluate the Efficacy and Safety of Two Marketed Investigational Products in Children With Diaper Rash	Completed	NCT00219466	Phase 4
16	Evaluation of 2 Interferon γ Assays in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT	Completed	NCT00647205	Phase 4
17	Remineralisation of White Spot Lesions by Elmex® gelée in Post-orthodontic Patients	Completed	NCT01329731	Phase 4	elmex® gelée;negative control (placebo)
18	MI Varnish for the Prevention of White Spot Lesions	Completed	NCT03446690	Phase 4	MI Varnish
19	Study of Nevirapine and Prednisone to Determine the Safety and Effectiveness in Preventing Nevirapine Associated Rash in Human Immunodeficiency Virus (HIV) Infected Patients	Completed	NCT02184299	Phase 4	Nevirapine;Prednisone
20	Lumefantrine in Venous Plasma Versus Dried Capillary Blood Spot	Completed	NCT02742285	Phase 4	Artemether + lumefantrine
21	Therapeutic Effect of Two Fluoride Varnishes on White Spot Lesions: a Clinical Study	Completed	NCT00723515	Phase 4	sodium fluoride;sodium fluoride calcium fluoride
22	MI Varnish and MI Paste Plus in a Caries Prevention and Remineralization Study	Completed	NCT02424097	Phase 4	CPP-ACP 5% sodium fluoride varnish & 900ppm fluoride paste;1,100pm F-toothpaste and 0.5%NaF rinse
23	Caries-preventive Effect of a Dentifrice Containing 5,000 Ppm Fluoride in Orthodontic Patients	Completed	NCT01768390	Phase 4
24	Genotype Based Personalized Prescription of Nevirapine	Completed	NCT00986063	Phase 4
25	Study to Evaluate the Effect of a Nu Skin Product and Device for Brown Spots	Completed	NCT01149876	Phase 4	Tretinoin cream 0.05
26	Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants	Completed	NCT00702507	Phase 4	0.25 % Miconazole Nitrate Ointment
27	Selection of Immunosuppression in Kidney Transplant Recipients Depending on Pre-transplant Donor-specific T-cell Reactivity.	Completed	NCT01195194	Phase 4	PRE-TRANSPLANT (PRE=before)
28	Efficacy of Pentoxifylline on Chronic Kidney Disease	Completed	NCT00155246	Phase 4	pentoxifylline (drug)
29	Subcutaneous Amifostine Safety Study	Completed	NCT00158041	Phase 4	Amifostine administered subcutaneously
30	Comparison of the Effect of Fluoride Remineralizer Gel and Foam	Completed	NCT02490592	Phase 4
31	Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy	Completed	NCT01797861	Phase 4
32	SIGnificance of Routine Hysteroscopy Prior to a First 'in Vitro Fertilization'(IVF) Treatment Cycle	Completed	NCT01242852	Phase 4
33	A Study of Vacyless® Versus Valtrex® in Patients With Herpes Zoster	Completed	NCT02152800	Phase 4	valacyclovir hydrocholoride
34	Impact of Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in Lampung Province, Sumatra	Completed	NCT01389557	Phase 4	Dihydroartemisinin-piperaquine with primaquine
35	Bipolar Study in Adults at Least 18 Years of Age	Completed	NCT00067938	Phase 4	lamotrigine
36	A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nep	Completed	NCT00168857	Phase 4	telmisartan;losartan
37	FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra	Completed	NCT01656148	Phase 4	Fampridine-SR
38	Salicylic Acid Peels Combined With 4% Hydroquinone in the Treatment of Moderate to Severe Melasma in Hispanic Women	Completed	NCT00616239	Phase 4	20-30% Salicylic Acid peels to the right side of the face;20-30% Salicylic Acid peels to the left side of the face
39	Use of the Contura™ Catheter in Intermediate-Risk, Pathological Stage 0, I, or II (Up to 3.0 cm) Breast Cancer Patients	Completed	NCT00882089	Phase 4
40	Oral Contraceptive Efficacy and Body Weight	Completed	NCT00662454	Phase 4	ethinyl estradiol / levonorgestrel;ethinyl estradiol / levonorgestrel
41	Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail	Completed	NCT02961998	Phase 4	Celecoxib;Sorafenib
42	A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children naïve to, or in Previous Receipt of the AS03B Adjuvanted H1N1 (2009)	Completed	NCT02143882	Phase 4	Fluenz
43	Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-treatment Patients With Chronic Hepatitis C：An Open-label Control Study in China	Completed	NCT02898922	Phase 4
44	Comparison of Efficacy of Intralesional Triamcinolone Injection and Clobetasol Propionate Ointment for Psoriatic Nails	Completed	NCT01703325	Phase 4	0.1% triamcinolone , 0.05% clobetasol propionate ointment
45	Prednisolone Pharmacokinetics in Severe Asthma	Completed	NCT00662298	Phase 4	prednisolone
46	Use of Fish Oils to Prevent Atrial Mechanical Stunning and Atrial Remodeling Due to Atrial Arrhythmia	Completed	NCT00232232	Phase 4	Fish oil
47	NOW Thai HAART Study	Completed	NCT00367731	Phase 4	Highly Active Antiretroviral Treatment (combination of :NRTI, NNRTI,or PI)
48	CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial	Completed	NCT00847912	Phase 4	5-fluorouracil;Placebo, vehicle control
49	Carotene and Retinol Efficacy Trial	Completed	NCT00712647	Phase 4	Beta Carotene and Retinol
50	Nevirapine Drug Levels in HIV Positive Patients Also Receiving Rifampicin for Tuberculosis	Completed	NCT00617643	Phase 4	Nevirapine without dose escalation;Nevirapine initiation with dose escalation

Search NIH Clinical Center for Exanthem

Cochrane evidence based reviews: exanthema

Sources

Genetic Tests for Exanthem

Sources

Anatomical Context for Exanthem

MalaCards organs/tissues related to Exanthem:

³⁸

Skin, Testes, Lung, Kidney, Eye, Bone, Brain

Sources

Publications for Exanthem

Articles related to Exanthem:

(show top 50) (show all 263)

#	Title	Authors	Year
1	50 Years Ago in The Journal of Pediatrics: Atypical Exanthem after Exposure to Natural Measles: Eleven Cases in Children Previously Inoculated with Killed Vaccine. ( 29389454 )	Toltzis P.	2018
2	Ten-year-old traveller with fever and an exceptional exanthem. ( 29314380 )	Osowicki J....SauvAc L.	2018
3	Ten-year-old traveller with fever and an exceptional exanthem. ( 29314384 )		2018
4	Acral-accentuated exanthem in an infant with parechovirus meningitis. ( 29205494 )	Lee D....Chong J.	2018
5	Unilateral laterothoracic exanthem. ( 28754336 )	Lozano-Masdemont B.	2017
6	Exanthem und Ekzem bei einem anderthalbjAohrigen Jungen. ( 28214315 )	Thielking F....FAPlster-Holst R.	2017
7	Acute localized exanthem due to Coxsackievirus A4. ( 28956547 )	Drago F....Parodi A.	2017
8	Dengue-Fieber und die Differenzialdiagnosen zu Exanthem, Fieber und Kopfschmerzen nach Fernreise. ( 28140551 )	Tjandra E.T....SunderkAPtter C.	2017
9	Can Unilateral Pityriasis Rosea be Considered a Form of Superimposed Lateralized Exanthem? ( 28764276 )	Drago F....Parodi A.	2017
10	Image Gallery: Flagellate bullous exanthem in chikungunya. ( 29052889 )	Vinay K....Dogra S.	2017
11	Superimposed lateralized exanthem in a 30-year-old woman. ( 28893877 )	AlcA!ntara-Reifs C.M....Salido-Vallejo R.	2017
12	Epstein-Barr virus exanthem in an adult patient with myelodysplastic syndrome. ( 29274098 )	Drago F....Rebora A.	2017
13	Assessment of histopathological features of maculopapular viral exanthem and drug-induced exanthem. ( 28914958 )	Singh S....Kabra S.K.	2017
14	IgA multiple myeloma in a patient with an IgG pemphigus foliaceus-like exanthem. ( 28856664 )	Lee N....Saavedra A.P.	2017
15	TherapierefraktAores Exanthem eines sechs Monate alten SAouglings. ( 29228485 )	Weingast J....Radakovic S.	2017
16	Pityriasis Rosea, Gianotti-Crosti Syndrome, Asymmetric Periflexural Exanthem, Papular-Purpuric Gloves and Socks Syndrome, Eruptive Pseudoangiomatosis, and Eruptive Hypomelanosis: Do Their Epidemiological Data Substantiate Infectious Etiologies? ( 27103975 )	Chuh A....Lee A.	2016
17	A mini-epidemic of eruptive hypomelanosis in three children of the same family; the first piece of epidemiological evidence for an infectious cause of a novel paraviral exanthem. ( 27038439 )	Chuh A....Bharatia P.	2016
18	Lateralized exanthem mimicking figurate inflammatory dermatosis of infancy after methimazole therapy. ( 27272160 )	Arrigo T....Altavilla D.	2016
19	Image Gallery: A case of unilateral laterothoracic exanthem. ( 27996140 )	Woo S.H....Park J.	2016
20	Exanthem subitum (human herpesvirus-6 reactivation) after autologous stem cell transplantation. ( 26918962 )	Schlaweck S....Mayer K.	2016
21	Coxsackievirus A6 Polymorphic Exanthem in Israeli Children. ( 26463513 )	Renert-Yuval Y....Molho-Pessach V.	2016
22	"Tache noire": diagnostic clue in a febrile exanthem. ( 28038854 )	Velasco-Tamariz V....MaroA+as-JimAcnez L.	2016
23	Anogenital allergic contact dermatitis caused by methylchloroisothiazolinone, methylisothiazolinone and topical clotrimazole with subsequent generalized exanthem triggered by oral fluconazole. ( 27040872 )	Nasir S....Goldsmith P.	2016
24	Urticarial exanthem associated with Capnocytophaga canimorsus bacteremia after a dog bite. ( 27051842 )	Jordan C.S....Mengden S.J.	2016
25	Eruptive hypomelanosis in a child, a new viral exanthem. ( 26728822 )	Zawar V....Chuh A.	2016
26	Stammbetontes Exanthem mit Allgemeinsymptomatik. ( 26972204 )	Delavari D....Hartmann M.	2016
27	Monitoring of human herpesviruses-6 and -7 DNA in saliva samples during the acute and convalescent phases of exanthem subitum. ( 27648817 )	Miyazaki Y....Yamada M.	2016
28	Purpuric exanthem caused by Ross River virus infection. ( 25551310 )	Allanson B....Wood B.A.	2015
29	Febrile Exanthem with Hyperferritinemia. ( 26705442 )	Caputo G.M....Ryan E.F.	2015
30	Localized exanthem due to echovirus 9. ( 25919440 )	Drago F....Parodi A.	2015
31	Unilateral Laterothoracic Exanthem. ( 26187001 )	Leung A.K....Barankin B.	2015
32	Unilateral Exanthem. ( 26120168 )	George A....Kanish B.	2015
33	Vesiculobullous viral exanthem due to chikungunya in an infant. ( 25593800 )	Singh N....Dhodapkar R.	2014
34	Aminopenicillin-associated exanthem: lymphocyte transformation testing revisited. ( 25323308 )	Trautmann A....Kerstan A.	2014
35	Eruptive hypomelanosis: a novel exanthem associated with viral symptoms in children. ( 25229328 )	Zawar V....Chuh A.	2014
36	Superimposed lateralized exanthem of childhood: report of a case related to adenovirus infection. ( 24635078 )	Niedermeier A....Happle R.	2014
37	Unilateral laterothoracic or asymmetric periflexural exanthem: is time to change the name of the disease? ( 25267301 )	Drago F....Rebora A.	2014
38	Black heel (talon noir) associated with a viral exanthem. ( 24222298 )	Sardana K....Sagar V.	2013
39	Unilateral laterothoracic exanthem. ( 21989468 )	Gragasin F.S....Metelitsa A.I.	2012
40	Acetaminophen-induced exanthem of the breasts. ( 22838093 )	Arora R....Maddox C.L.	2012
41	Gianotti-Crosti syndrome, pityriasis rosea, asymmetrical periflexural exanthem, unilateral mediothoracic exanthem, eruptive pseudoangiomatosis, and papular-purpuric gloves and socks syndrome: a brief review and arguments for diagnostic criteria. ( 24470919 )	Chuh A....Sciallis G.	2012
42	Febrile illness with papular and vesicular exanthem and ulceronecrotic plaques. ( 23106676 )	Castelo-Soccio L.A....Shah K.N.	2012
43	Generalized purpuric drug exanthem with hemorrhagic plaques following bendamustine chemotherapy in a patient with B-prolymphocytic leukemia. ( 22290027 )	Gavini A....Olszewski A.J.	2012
44	Histopathology of measles exanthem: a case with characteristic features and eosinophils. ( 22725635 )	Sheikine Y....Zimarowski M.J.	2012
45	Drug-induced exanthem following dabigatran. ( 21881034 )	Whitehead H....Hummel J.	2011
46	Asymmetrical periflexural exanthem of childhood with concurrence of molluscum contagiosum infection. ( 21457157 )	Baek Y.S....Son S.B.	2011
47	A challenging case: Symmetrical drug related intertriginous and flexural exanthem, fixed drug eruption, or both? ( 22082466 )	Ozkaya E....Babuna G.	2011
48	Papular exanthem discloses acute myeloid leukaemia: interphase fluorescence in situ hybridization revealed deletion of p53 and gain at 8q22/8q24/Tel8q without trisomy 8. ( 19438543 )	Kaune K.M....Emmert S.	2010
49	Transient linear eruption: asymmetric periflexural exanthem or blaschkitis. ( 20609153 )	Arun B....Salim A.	2010
50	Image in medicine. An exanthem with an annular pattern in a 2-year-old girl. Atypical viral exanthem with an annular pattern. ( 20838712 )	Rodgers C.J....Tey H.L.	2010

Sources

Genes for Exanthem

Genes related to Exanthem (0 elite genes):

(show all 20)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Implication
1	CD40LG	CD40 Ligand	Protein Coding	18.5	DISEASES inferred ¹⁴ GeneCards inferred via : DISEASES inferred (show sections)
2	EGFR	Epidermal Growth Factor Receptor	Protein Coding	17.58	DISEASES inferred ¹⁴ GeneCards inferred via : DISEASES inferred (show sections)
3	IL1RN	Interleukin 1 Receptor Antagonist	Protein Coding	17.12	DISEASES inferred ¹⁴ GeneCards inferred via : DISEASES inferred (show sections)
4	NLRP3	NLR Family Pyrin Domain Containing 3	Protein Coding	16.97	DISEASES inferred ¹⁴ GeneCards inferred via : DISEASES inferred (show sections)
5	CD79A	CD79a Molecule	Protein Coding	16.75	DISEASES inferred ¹⁴ GeneCards inferred via : DISEASES inferred (show sections)
6	TLR9	Toll Like Receptor 9	Protein Coding	16.74	DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : DISEASES inferred (show sections)
7	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	16.62	DISEASES inferred ¹⁴ GeneCards inferred via : DISEASES inferred (show sections)
8	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	16.57	DISEASES inferred ¹⁴ GeneCards inferred via : DISEASES inferred (show sections)
9	CRP	C-Reactive Protein	Protein Coding	16.51	DISEASES inferred ¹⁴ GeneCards inferred via : DISEASES inferred (show sections)
10	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	16.36	DISEASES inferred ¹⁴ GeneCards inferred via : DISEASES inferred (show sections)
11	TNFRSF1B	TNF Receptor Superfamily Member 1B	Protein Coding	16.23	DISEASES inferred ¹⁴ GeneCards inferred via : DISEASES inferred (show sections)
12	HSPG2	Heparan Sulfate Proteoglycan 2	Protein Coding	16.02	DISEASES inferred ¹⁴ GeneCards inferred via : DISEASES inferred (show sections)
13	TRIM21	Tripartite Motif Containing 21	Protein Coding	16.01	DISEASES inferred ¹⁴ GeneCards inferred via : DISEASES inferred (show sections)
14	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	15.97	DISEASES inferred ¹⁴ GeneCards inferred via : DISEASES inferred (show sections)
15	TNF	Tumor Necrosis Factor	Protein Coding	15.93	DISEASES inferred ¹⁴ GeneCards inferred via : DISEASES inferred (show sections)
16	IL2	Interleukin 2	Protein Coding	15.81	DISEASES inferred ¹⁴ GeneCards inferred via : DISEASES inferred (show sections)
17	KALRN	Kalirin RhoGEF Kinase	Protein Coding	15.79	DISEASES inferred ¹⁴ GeneCards inferred via : DISEASES inferred (show sections)
18	TNFRSF1A	TNF Receptor Superfamily Member 1A	Protein Coding	15.68	DISEASES inferred ¹⁴ GeneCards inferred via : DISEASES inferred (show sections)
19	MAP2K7	Mitogen-Activated Protein Kinase Kinase 7	Protein Coding	15.66	DISEASES inferred ¹⁴ GeneCards inferred via : DISEASES inferred (show sections)
20	SENP8	SUMO/Sentrin Peptidase Family Member, NEDD8 Specific	Protein Coding	6.66	DISEASES inferred ¹⁴

Sources

Variations for Exanthem

Sources

Expression for Exanthem

Search GEO for disease gene expression data for Exanthem.

Sources

Pathways for Exanthem

Pathways related to Exanthem according to GeneCards Suite gene sharing:

(show top 50) (show all 100)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶⁰ Show member pathways ILK Signaling ⁶⁰ MAPK Signaling ⁶⁰ Molecular Mechanisms of Cancer ⁶⁰ Rho Family GTPases ⁶⁰	13.86	CD40LG EGFR ERBB2 HRAS HSPG2 IL2
2	PEDF Induced Signaling ⁶⁰ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁰ Cytokine-cytokine receptor interaction ³⁶ Endothelin-1 Signaling Pathway ⁶⁰ Glucocorticoid Receptor Signaling ⁶⁰ IL-6 Pathway ⁶⁰ MIF Mediated Glucocorticoid Regulation ⁶⁰ MIF Regulation of Innate Immune Cells ⁶⁰ NFAT Signaling and Lymphocyte Interactions ⁶⁰ PGC1Alpha Pathway ⁶⁰ RAR-Gamma-RXR-Alpha Degradation ⁶⁰ STAT3 Pathway ⁶⁰	13.74	CD40LG EGFR ERBB2 HRAS IL2 KRAS
3	TGF-Beta Pathway ⁶⁰ Show member pathways JAK-STAT Pathway ⁶⁰ JNK Pathway ⁶⁰ MAPK Family Pathway ⁶⁰ Regulation of eIF4 and p70S6K ⁶⁰ SOCS Pathway ⁶⁰	13.64	EGFR ERBB2 HRAS IL2 KRAS MAP2K7
4	Class I MHC mediated antigen processing and presentation ⁶² Show member pathways Adaptive Immune System ⁶² Antigen processing- Ubiquitination and Proteasome degradation ⁶²	13.55	CD40LG CD79A EGFR ERBB2 HRAS KRAS
5	Akt Signaling ⁶⁰ Show member pathways p38 Signaling ⁶⁰ Tec Kinases Signaling ⁶⁰	13.4	CD40LG EGFR ERBB2 HRAS IL2 KRAS
6	Nanog in Mammalian ESC Pluripotency ⁶⁰ Show member pathways 14-3-3 Induced Intracellular Signaling ⁶⁰ eNOS Signaling ⁶⁰ GSK3 Signaling ⁶⁰	13.36	EGFR ERBB2 HRAS IL2 KRAS TNF
7	Cytokine Signaling in Immune system ⁶² Show member pathways Signaling by Interleukins ⁶²	13.33	CD40LG EGFR ERBB2 HRAS IL1RN IL2
8	PAK Pathway ⁶⁰ Show member pathways Antioxidant Action of Vitamin-C ⁶⁰ Epithelial Adherens Junctions ⁶⁰	13.31	CD40LG EGFR ERBB2 HRAS IL2 KRAS
9	Phospholipase-C Pathway ⁶⁰ Show member pathways PTEN Pathway ⁶⁰	13.16	CD79A EGFR HRAS HSPG2 IL2 KRAS
10	Innate Immune System ⁶² Show member pathways Immune System ⁶² Neutrophil degranulation ⁶²	13.15	CD40LG CD79A CRP EGFR ERBB2 HRAS
11	Endometrial cancer ³⁶ Show member pathways Acute myeloid leukemia ³⁶ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶² Colorectal cancer ³⁶ EGFR tyrosine kinase inhibitor resistance ³⁶ Glioma ³⁶ Melanoma ³⁶ Non-small cell lung cancer ³⁶ Prostate cancer ³⁶ Signal transduction PTEN pathway ²¹ Signaling Pathways in Glioblastoma ¹ Thyroid cancer ³⁶	13.13	EGFR ERBB2 HRAS KRAS MAP2K7 MTOR
12	IL-2 Pathway ⁶⁰ Show member pathways ErbB Family Pathway ⁶⁰ ErbB2-ErbB3 Heterodimers ⁶⁰ ErbB4 Pathway ⁶⁰ Growth Hormone Signaling ⁶⁰ HMGB1 Pathway ⁶⁰ IL-4 Pathway ⁶⁰ LPS Stimulated MAPK Signaling ⁶⁰ PACAP Signaling ⁶⁰ PI3K Signaling in B-Lymphocyte ⁶⁰ Prolactin Signaling ⁶⁰ Thrombopoietin Pathway ⁶⁰ TREM1 Pathway ⁶⁰ UVC-Induced MAPK Signaling ⁶⁰	13.1	CD79A EGFR ERBB2 HRAS IL2 KRAS
13	PI3K-Akt signaling pathway ³⁶ Show member pathways Human papillomavirus infection ³⁶	13.07	EGFR HRAS IL2 KRAS MTOR TNF
14	Toll-Like receptor Signaling Pathways ⁶¹ Show member pathways IL-1 Family Signaling Pathways ⁶¹ Immune response IL-1 signaling pathway ²¹ Immune response TLR3 and TLR4 induce TICAM1-specific signaling pathway ²¹ Inflammasome Activation Pathways ⁶¹ Mucin expression in CF via TLRs, EGFR signaling pathways ²¹ NOD-like receptor signaling pathway ³⁶ NOD-like Receptor Signaling Pathways ⁶¹ Pathogen or Damage-activated C-Type Lectin Receptor Signaling Pathways ⁶¹	13.02	EGFR HRAS IL1RN KRAS MAP2K7 NLRP3
15	TNFR1 Pathway ⁶⁰ Show member pathways Apoptosis and survival TNFR1 signaling pathway ²¹ Apoptosis through Death Receptors ⁶⁰ Apoptotic Pathways Triggered By HIV1 ⁶⁰ DR3 Signaling ⁶⁰ Fas Signaling ⁶⁰ GITR Pathway ⁶⁰ HIV-1 Nef- Negative effector of Fas and TNF-alpha ¹ Stimulation of the cell death response by PAK-2p34 ⁶² TNF alpha Signaling Pathway ¹ TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway ¹ TNF Signaling ⁶⁰ TRAIL Pathway ⁶⁰ TWEAK Pathway ⁶⁰	12.97	HRAS KRAS MAP2K7 TNF TNFRSF1A TNFRSF1B
16	Development Angiotensin activation of ERK ²¹ Show member pathways Cell adhesion Integrin inside-out signaling ²¹ Development ACM2 and ACM4 activation of ERK ²¹ Development Angiotensin signaling via PYK2 ²¹ Development EDNRB signaling ²¹ Development EPO-induced MAPK pathway ²¹ Development G-Proteins mediated regulation MARK-ERK signaling ²¹ Signal transduction IP3 signaling ²¹	12.96	CD79A EGFR HRAS KRAS TNF TNFRSF1A
17	Pathways in cancer ³⁶	12.94	EGFR ERBB2 HRAS IL2 KRAS MTOR
18	Influenza A ³⁶ Show member pathways Herpes simplex infection ³⁶ Measles ³⁶	12.9	IL2 MAP2K7 NLRP3 TLR9 TNF TNFRSF1A
19	Common Cytokine Receptor Gamma-Chain Family Signaling Pathways ⁶¹ Show member pathways Adipokines and Insulin Signaling Pathways ⁶¹ Development Thrombopoietin-regulated cell processes ²¹ IL-15 Signaling Pathways ⁶¹ IL-2 Signaling Pathways ⁶¹ IL-21 Signaling Pathways ⁶¹ IL-4 Signaling Pathways ⁶¹ IL-7 Signaling Pathways ⁶¹ IL-9 Pathway ⁶⁰ IL-9 Signaling Pathways ⁶¹ Immune response IL-9 signaling pathway ²¹	12.86	HRAS IL2 KRAS MTOR TNF TNFRSF1A
20	MAPK signaling pathway ³⁶ ¹	12.85	EGFR HRAS KRAS MAP2K7 TNF TNFRSF1A
21	Gastric cancer ³⁶ Show member pathways Breast cancer ³⁶ Hepatocellular carcinoma ³⁶	12.84	EGFR ERBB2 HRAS KRAS MTOR
22	Downstream signaling events of B Cell Receptor (BCR) ⁶² Show member pathways Activation of RAS in B cells ⁶² Signaling by the B Cell Receptor (BCR) ⁶²	12.83	CD79A EGFR ERBB2 HRAS KRAS MTOR
23	Development HGF signaling pathway ²¹ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²¹ Apoptosis and survival NGF signaling pathway ²¹ Apoptosis and survival Role of CDK5 in neuronal death and survival ²¹ Development Neurotrophin family signaling ²¹ MET activates PTPN11 ⁶² MET activates STAT3 ⁶² Neurotrophin signaling pathway ³⁶ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.8	ERBB2 HRAS KRAS MAP2K7 MTOR
24	Development Endothelin-1/EDNRA signaling ²¹ Show member pathways Cytoskeleton remodeling FAK signaling ²¹ Development Endothelin-1/EDNRA transactivation of EGFR ²¹ GnRH signaling pathway ³⁶ Inflammatory mediator regulation of TRP channels ³⁶	12.75	EGFR HRAS KRAS MAP2K7 MTOR
25	NF-KappaB Family Pathway ⁶⁰ Show member pathways NF-KappaB (p50-p65) Pathway ⁶⁰	12.74	CD40LG EGFR IL2 TLR9 TNF TNFRSF1A
26	Immune response IL-23 signaling pathway ²¹ Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶⁰ Development Angiopoietin - Tie2 signaling ²¹ Development PDGF signaling via STATs and NF-kB ²¹ IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²¹ Rac1/Pak1/p38/MMP-2 pathway ¹	12.7	EGFR ERBB2 HRAS IL2 KRAS TNF
27	Relaxin signaling pathway ³⁶ Show member pathways Endocrine resistance ³⁶ Estrogen signaling pathway ³⁶ Relaxin receptors ⁶²	12.69	EGFR ERBB2 HRAS KRAS MAP2K7 MTOR
28	Immune response Fc epsilon RI pathway ²¹ Show member pathways Fc epsilon RI signaling pathway ³⁶ Fc-epsilon receptor I signaling in mast cells ¹ Immune response BCR pathway ²¹ VEGF signaling pathway ³⁶	12.68	CD79A HRAS KRAS MAP2K7 TNF
29	TRAF Pathway ⁶⁰ Show member pathways 14-3-3 Induced Apoptosis ⁶⁰ TNF Superfamily Pathway ⁶⁰ Toll-Like Receptors Pathway ⁶⁰	12.67	CD40LG HRAS MAP2K7 TLR9 TNF TNFRSF1A
30	Toll-like receptor signaling pathway ¹ ³⁶ Show member pathways Chagas disease (American trypanosomiasis) ³⁶	12.64	IL2 MAP2K7 TLR9 TNF TNFRSF1A
31	MicroRNAs in cancer ³⁶	12.62	EGFR ERBB2 HRAS KRAS MTOR
32	Immune response NFAT in immune response ²¹ Show member pathways Immune response CD28 signaling ²¹ Immune response ICOS pathway in T-helper cell ²¹ Immune response T cell receptor signaling pathway ²¹	12.62	CD40LG CD79A HRAS IL2 MAP2K7 TNF
33	4-1BB Pathway ⁶⁰ Show member pathways CD27 Pathway ⁶⁰ CD40 Signaling ⁶⁰ CMV and MAPK Pathways ⁶⁰ NF-KappaB Activation by EBV ⁶⁰ NF-kappaB Activation by Viruses ⁶⁰ PKR Pathway ⁶⁰ SUMO Pathway ⁶⁰ TNFR2 Pathway ⁶⁰	12.6	CD40LG EGFR HRAS KRAS MAP2K7 TNF
34	Prolactin Signaling Pathway ³⁶ ¹ Show member pathways Development Prolactin receptor signaling ²¹ Leptin signaling pathway ¹	12.59	ERBB2 HRAS IL1RN KRAS MTOR
35	Kaposi's sarcoma-associated herpesvirus infection ³⁶ Show member pathways Hepatitis B ³⁶	12.59	HRAS HSPG2 KRAS MAP2K7 MTOR TNF
36	ErbB signaling pathway ³⁶ ¹ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁵⁷ Renal cell carcinoma ³⁶ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.58	EGFR ERBB2 HRAS KRAS MAP2K7 MTOR
37	Development EGFR signaling pathway ²¹ Show member pathways Development ERBB-family signaling ²¹ EGF Pathway ⁶⁰ EGFR Signaling Pathway ⁶³ ErbB receptor signaling network ¹	12.55	EGFR ERBB2 HRAS KRAS MAP2K7 MTOR
38	HTLV-I infection ³⁶	12.52	HRAS IL2 KRAS TNF TNFRSF1A
39	Apoptosis Pathway ⁶⁸ Show member pathways Akt Pathway ⁶⁸ NF-kappaB Pathway ⁶⁸	12.52	EGFR ERBB2 HRAS IL2 KRAS MTOR
40	T cell receptor signaling pathway ³⁶ Show member pathways T-Cell antigen Receptor (TCR) Signaling Pathway ¹ T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection ¹	12.5	CD40LG HRAS IL2 KRAS MAP2K7 TNF
41	Jak-STAT signaling pathway (KEGG) ³⁶ Show member pathways B-Cell Development ⁶⁰ IL-7 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types ⁶¹ Interleukin-19, 20, 22, 24 ⁶² Jak/STAT Signaling Pathway ⁶¹	12.44	EGFR HRAS IL2 MTOR
42	MET promotes cell motility ⁶² Show member pathways Alpha 6 Beta 4 signaling pathway ¹ Laminin interactions ⁶² MET activates PTK2 signaling ⁶² MET activates RAP1 and RAC1 ⁶² MET activates RAS signaling ⁶² MET interacts with TNS proteins ⁶² MET Receptor Activation ⁶² MET receptor recycling ⁶² Signaling by MET ⁶²	12.42	HRAS HSPG2 KRAS MTOR
43	TNF signaling (REACTOME) ¹ Show member pathways Death Receptor Signalling ⁶² Regulation of TNFR1 signaling ⁶² TNF signaling ⁶² TNFR1-induced NFkappaB signaling pathway ⁶² TNFR1-induced proapoptotic signaling ⁶² TNFR1-mediated ceramide production ⁶²	12.41	MAP2K7 TNF TNFRSF1A TNFRSF1B
44	Signaling by ERBB2 ⁶² Show member pathways Downregulation of ERBB2 signaling ⁶² Downregulation of ERBB2-ERBB3 signaling ⁶² ERBB2 Activates PTK6 Signaling ⁶² ERBB2 Regulates Cell Motility ⁶² GRB2 events in ERBB2 signaling ⁶² GRB7 events in ERBB2 signaling ⁶² PI3K events in ERBB2 signaling ⁶² PI3K events in ERBB4 signaling ⁶² PLCG1 events in ERBB2 signaling ⁶² SHC1 events in ERBB2 signaling ⁶² SHC1 events in ERBB4 signaling ⁶²	12.39	EGFR ERBB2 HRAS KRAS
45	NF-kappaB Signaling ⁴	12.37	CD40LG CD79A IL1RN IL2 TLR9 TNF
46	G-protein signaling Ras family GTPases in kinase cascades (scheme) ²¹ Show member pathways Activation of the AP-1 family of transcription factors ⁶² Immune response Oncostatin M signaling via MAPK in human cells ²¹ MAPK Cascade ¹ Oncostatin M Signaling Pathway ¹	12.33	HRAS KRAS MAP2K7 MTOR
47	Apoptosis and Autophagy ⁴	12.33	CD40LG TNF TNFRSF1A TNFRSF1B
48	MAPK Signaling: Mitogen Stimulation Pathway ⁶¹ Show member pathways Akt Signaling Pathway ⁶¹	12.33	EGFR ERBB2 HRAS KRAS MTOR
49	VEGF Signaling Pathway ⁶³ ⁵⁷ Show member pathways Nanoparticle-mediated activation of receptor signaling ¹ TGF-beta Signaling ⁶³	12.31	EGFR HRAS KRAS MAP2K7
50	Colorectal Cancer Metastasis ⁶⁰	12.3	EGFR KRAS TLR9 TNF TNFRSF1A

Sources

GO Terms for Exanthem

Cellular components related to Exanthem according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	9.81	CD40LG CRP EGFR HSPG2 IL1RN IL2
2	extracellular region	GO:0005576	9.7	CD40LG CRP EGFR HSPG2 IL1RN IL2
3	membrane raft	GO:0045121	9.1	CD79A EGFR KRAS TNF TNFRSF1A TNFRSF1B

Biological processes related to Exanthem according to GeneCards Suite gene sharing:

(show all 36)

#	Name	GO ID	Score	Top Affiliating Genes
1	regulation of cell proliferation	GO:0042127	9.96	EGFR TNF TNFRSF1A TNFRSF1B
2	MAPK cascade	GO:0000165	9.88	EGFR ERBB2 HRAS IL2 KRAS TNF
3	positive regulation of protein kinase B signaling	GO:0051897	9.87	EGFR ERBB2 MTOR TNF
4	positive regulation of cell growth	GO:0030307	9.85	EGFR ERBB2 IL2
5	cell surface receptor signaling pathway	GO:0007166	9.85	CD79A EGFR ERBB2 HRAS TNFRSF1A TNFRSF1B
6	tumor necrosis factor-mediated signaling pathway	GO:0033209	9.84	CD40LG TNF TNFRSF1A TNFRSF1B
7	negative regulation of NF-kappaB transcription factor activity	GO:0032088	9.83	NLRP3 TLR9 TRIM21
8	positive regulation of JNK cascade	GO:0046330	9.83	HRAS TLR9 TNF
9	positive regulation of NF-kappaB transcription factor activity	GO:0051092	9.83	CD40LG KRAS NLRP3 TLR9 TNF
10	response to glucocorticoid	GO:0051384	9.81	IL1RN KRAS TNF
11	positive regulation of epithelial cell proliferation	GO:0050679	9.8	EGFR ERBB2 HRAS
12	positive regulation of gene expression	GO:0010628	9.8	CRP ERBB2 HRAS KRAS MTOR TLR9
13	positive regulation of smooth muscle cell proliferation	GO:0048661	9.79	EGFR MTOR TNF
14	epidermal growth factor receptor signaling pathway	GO:0007173	9.79	EGFR HRAS KRAS
15	negative regulation of inflammatory response	GO:0050728	9.78	IL2 NLRP3 TNFRSF1A TNFRSF1B
16	cellular response to growth factor stimulus	GO:0071363	9.77	EGFR ERBB2 TNFRSF1B
17	cellular response to amino acid stimulus	GO:0071230	9.77	EGFR MTOR TNF
18	intrinsic apoptotic signaling pathway in response to DNA damage	GO:0008630	9.76	TNF TNFRSF1A TNFRSF1B
19	positive regulation of